PROTAC ERα Degrader-13

PROTAC ERα Degrader-13 is an orally active PROTAC molecule that efficiently and selectively degrades ERα (DC50 = 3.78 nM) . PROTAC ERα Degrader-13 has the characteristics of strong anti proliferation (IC50 = 0.6 nM), induction of apoptosis, and overcoming drug resistance in MCF-7 cells. PROTAC ERα Degrader-13 has good safety and no significant organ toxicity. PROTAC ERα Degrader-13 can be used for cancer research. (Pink: ERα Ligand (HY-12864) ; Blue: VHL Ligand (HY-125845) ; Black: Linker (HY-W040168) ) [1]

Product Specifications

Target

Apoptosis; Estrogen Receptor/ERR; PROTACs

Related Pathways

Apoptosis; PROTAC; Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Smiles

CC/C(C1=CC=C(F)C=C1Cl)=C(C2=CC=C(/C=C/C(NCCOCCOCCC(N[C@H](C(N3C[C@H](O)C[C@H]3C(NCC4=CC=C(C5=C(C)N=CS5)C=C4)=O)=O)C(C)(C)C)=O)=O)C=C2)\C6=CC(C=NN7)=C7C=C6

Molecular Formula

C55H61ClFN7O7S

Molecular Weight

1018.63

References & Citations

[1]Bao X, et al. Highly potent and selective degrader targeting ERα to improve the treatment outcomes of breast cancer. Eur J Med Chem. 2026 Jan 5;301:118199.